^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    TL118

    i
    Other names: TL118
    Associations

    News

    Trials
    Company:
    Teligene
    Drug class:
    Trk inhibitor
    Related drugs:
    Associations

    News

    Trials
    4ms
    A Study to Evaluate the Efficacy and Safety of TL118 in Solid Tumors Patients (clinicaltrials.gov)
    P2, N=60, Recruiting, Teligene US | Not yet recruiting --> Recruiting | Trial completion date: Dec 2025 --> Apr 2026 | Initiation date: May 2024 --> Mar 2023 | Trial primary completion date: Dec 2025 --> Aug 2025
    Enrollment open • Trial completion date • Trial initiation date • Trial primary completion date
    |
    NTRK1 (Neurotrophic tyrosine kinase, receptor, type 1) • NTRK3 (Neurotrophic tyrosine kinase, receptor, type 3) • NTRK2 (Neurotrophic tyrosine kinase, receptor, type 2)
    |
    TL118
    9ms
    A Study to Evaluate the Efficacy and Safety of TL118 in Solid Tumors Patients (clinicaltrials.gov)
    P2, N=60, Not yet recruiting, Teligene US | Initiation date: Jan 2024 --> May 2024
    Trial initiation date
    |
    NTRK1 (Neurotrophic tyrosine kinase, receptor, type 1) • NTRK3 (Neurotrophic tyrosine kinase, receptor, type 3) • NTRK2 (Neurotrophic tyrosine kinase, receptor, type 2)
    |
    NTRK1 fusion • NTRK3 fusion • NTRK2 fusion
    |
    TL118
    over1year
    A Study to Evaluate the Efficacy and Safety of TL118 in Solid Tumors Patients (clinicaltrials.gov)
    P2, N=60, Not yet recruiting, Teligene US
    New P2 trial
    |
    NTRK1 (Neurotrophic tyrosine kinase, receptor, type 1) • NTRK3 (Neurotrophic tyrosine kinase, receptor, type 3) • NTRK2 (Neurotrophic tyrosine kinase, receptor, type 2)
    |
    NTRK1 fusion • NTRK3 fusion • NTRK2 fusion
    |
    TL118